Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06846710 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
A Phase 1 study of Psoriasis, sponsored by Jiangsu Hansoh Pharmaceutical Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 132
- Enrollment target
- 9
- Study locations
NCT06846710 is a Phase 1 study of Psoriasis that is actively recruiting participants, run by Jiangsu Hansoh Pharmaceutical Co.. The registered enrollment target is 132 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (73% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT06846710, a Phase 1 study of Psoriasis, is actively recruiting participants, sponsored by Jiangsu Hansoh Pharmaceutical Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 132 participants
- Enrollment target
- 9
- Study locations
Study Summary
The study will be conducted in 2 parts (SAD for Part 1 and MAD for Part2). Part 1 is a single-center, randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability, immunogenicity, and PK of HS-20118 after a single oral dose in healthy participants. Part 2 is a multi-center, randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability, immunogenicity, PK, and PD of HS-20118 after multiple oral doses in patients with moderate to severe plaque psoriasis .
Conditions Studied
Interventions
- DRUG HS-20118
- OTHER HS-20118 placebo
Study Locations (9)
Florida
- Clinitiative - Floridian Clinical Research, LLC - Miami Lakes
- NuLine Clinical Trial Center (Network) - Pompano Beach
California
- Kinetic Clinical Research - Anaheim
Auckland
- Pacific Clinical Research Network (PCRN), Auckland - Takapuna
Christchurch
- Pacific Clinical Research Network (PCRN), Christchurch - Christchurch
Dunedin
- Momentum Clinical Research, Dunedin - Dunedin
Pukekohe
- Momentum Clinical Research, Pukekohe - Pukekohe
Upper Hutt
- Pacific Clinical Research Network (PCRN), Wellington - Upper Hutt
Wellington Region
- Momentum Clinical Research, Wellington - Mount Cook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2025-05-02 |
| Est. Completion | 2027-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06846710
The ClinicalTrials.gov registry entry for NCT06846710 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (73% lower). The listed sponsor is Jiangsu Hansoh Pharmaceutical Co., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which HS-20118 is the first listed.
NCT06846710 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Auckland.
Frequently Asked Questions
What is clinical trial NCT06846710 about?
NCT06846710 is a clinical study titled "Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118". The study will be conducted in 2 parts (SAD for Part 1 and MAD for Part2). Part 1 is a single-center, randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability, immunogenicity, and PK of HS-20118 after a single oral dose in healthy participants. Part 2 is a multi-...
What is the current status of trial NCT06846710?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 132 participants. The study started on 2025-05-02. Estimated completion is 2027-02-28.
What conditions does trial NCT06846710 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT06846710?
The interventions under investigation include: HS-20118 (DRUG), HS-20118 placebo (OTHER).
Who is sponsoring clinical trial NCT06846710?
This trial is sponsored by Jiangsu Hansoh Pharmaceutical Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06846710 being conducted?
This trial has 9 study locations across California, Florida, Auckland, Christchurch, Dunedin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
RECRUITING · Phase 1
-
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
RECRUITING · Phase 1
-
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
COMPLETED · Phase 1
-
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
COMPLETED · Phase 1
-
An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.